Tomonori Hirashima

Ishikiriseiki Hospital — Japan

Medicine · Health Sciences

40h-index12.9kcitations214works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(124), Lung Cancer Diagnosis and Treatment(58), Lung Cancer Research Studies(55), Colorectal Cancer Treatments and Studies(38), Cancer Immunotherapy and Biomarkers(29)

Publications213 total

Stereotactic body radiation therapy for multiple lung cancers in a patient with six primary cancers: a case report
Journal of Medical Case Reports·2024Open Access
MO56-1 Randomized phase II study of zoledronate dosing every 4 versus 8 weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Annals of Oncology·2023Open Access
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312)
Lung Cancer·2023· 2 cited
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small<scp>‐</scp>cell lung cancer in KEYNOTE‐407
Cancer Science·2023· 12 citedOpen Access
O13-4 Efficacy and intracranial activity of tepotinib in Japanese patients with MET exon 14 skipping (METex14) NSCLC (VISION)
Annals of Oncology·2022· 1 cited
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
JCI Insight·2022· 24 citedOpen Access
Aggressive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer with Resistance to Anti-Cancer Agents: a Case Report
Haigan·2022Open Access
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
Investigational New Drugs·2022· 5 cited
A case of renal cell carcinoma with late recurrence in the bilateral hilar lymph nodes twenty years after surgery
Respiratory Medicine Case Reports·2022· 2 citedOpen Access
A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
Respiratory Medicine Case Reports·2022· 3 citedOpen Access
Acromegaly Initially Presenting with Severe Infectious Diseases: A Case Report
JMA Journal·2022Open Access
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
2021· 1 citedOpen Access
Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19
Frontiers in Medicine·2021· 17 citedOpen Access
Scoring system for identifying Japanese patients with COVID-19 at risk of requiring oxygen supply: A retrospective single-center study
Journal of Infection and Chemotherapy·2021· 7 citedOpen Access
The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
Scientific Reports·2021· 6 citedOpen Access
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Targeted Oncology·2021· 13 citedOpen Access
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
BMC Cancer·2021· 32 citedOpen Access
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
Translational Lung Cancer Research·2021· 17 citedOpen Access
Clinical COVID-19 diagnostic methods: Comparison of reverse transcription loop-mediated isothermal amplification (RT-LAMP) and quantitative RT-PCR (qRT-PCR)
Journal of Clinical Virology·2021· 52 citedOpen Access
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer
JAMA Oncology·2021· 11 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Motohiro Tamiya(17), Shinji Atagi(15), Kazuhiko Nakagawa(14), Akihiro Tamiya(14), Norio Okamoto(14), Takayuki Shiroyama(13), Hidekazu Suzuki(13), Hidekazu Suzuki(13), Fumio Imamura(11), Toru Kumagai(11), Isamu Okamoto(10), Yoshihiko Taniguchi(10), Miyako Satouchi(9), Takashi Seto(8), Ayako Tanaka(8), Kazuhiro Asami(7), Makoto Nishio(7), Kenji Nakahama(7), Takako Inoue(7), Ichiro Kawase(7)